Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | CASR | P41180 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5470486 | 0.88 | LMNA (0.48) | SMN1; SMN2CYP3A4LMNACYP1A2CHRM2 | |
| SCHEMBL5470485 | 0.88 | LMNA (0.48) | SMN1; SMN2CYP3A4LMNACYP1A2CHRM2 | |
| SCHEMBL14532818 | 0.84 | SMN1; SMN2 (0.46) | SMN1; SMN2LMNACYP1A2ALDH1A1POLB | |
| SCHEMBL5479317 | 0.82 | LMNA (0.44) | SMN1; SMN2CYP3A4LMNACYP1A2CHRM2 | |
| SCHEMBL3034755 | 0.82 | CYP3A4 (0.44) | SMN1; SMN2CYP3A4LMNACYP1A2CHRM2 | |
| SCHEMBL5479312 | 0.82 | LMNA (0.44) | SMN1; SMN2CYP3A4LMNACYP1A2CHRM2 | |
| SCHEMBL31579895 | 0.81 | HTR1A (0.47) | SMN1; SMN2CYP3A4LMNACYP1A2CHRM2 | |
| SCHEMBL3653564 | 0.81 | CYP3A4 (0.43) | SMN1; SMN2CYP3A4LMNACYP1A2CHRM2 | |
| SCHEMBL5468813 | 0.81 | LMNA (0.61) | SMN1; SMN2CYP3A4LMNACYP1A2CHRM2 | |
| SCHEMBL5468817 | 0.81 | LMNA (0.61) | SMN1; SMN2CYP3A4LMNACYP1A2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA (SE) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | SMN1; SMN2 4397/4885CYP3A4 1522/4885LMNA 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.